Immuron begins clinical trial with second cohort in Travelan study

Immuron announced the second cohort of 34 participants have commenced the clinical trial to evaluate the efficacy of Travelan to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli, or ETEC. The clinical study is being led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US. The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of Travelan compared to a placebo in a controlled human infection model. The primary efficacy outcome is prevention and/or reduction of moderate to severe diarrhea. The first cohort in-patient stage of the study was completed in August 2023.